A phase I/II study (NCT03190174) has investigated the combination of nivolumab (an anti-PD-1 monoclonal antibody) with the mTOR inhibitor nab-rapamycin in different sarcoma types, including ES. The gene discussed is MTOR; the disease is sarcoma.